Amphastar P

Yahoo Finance • 28 days ago

NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. The retreat in oil prices provided temporary relief to a market that was volatil... Full story

Yahoo Finance • last month

Wells Fargo Sees Amphastar Pharmaceuticals, Inc.’s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts.Wells Fargo Sees Amphastar Pharmaceuticals, Inc.'s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth T... Full story

Yahoo Finance • 4 months ago

Amphastar Director Sells 16,679 Shares for $441,800

Key Points Floyd Petersen exercised and sold 16,679 shares of Amphastar in November, pocketing more than $441,000. He still retains about $2 million worth of shares. These 10 stocks could mint the next wave of millionaires › Floyd Peters... Full story

Yahoo Finance • 4 months ago

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO

(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Haloz... Full story

Yahoo Finance • 4 months ago

Will FDA Approval of an In‑House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative?

In December 2025, Amphastar Pharmaceuticals announced that the FDA approved its abbreviated new drug application for a teriparatide injection prefilled pen, deemed bioequivalent and therapeutically equivalent to Eli Lilly’s FORTEO, with pl... Full story

Yahoo Finance • 4 months ago

Amphastar Announces FDA Approval for Teriparatide Injection

RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") fo... Full story

Yahoo Finance • 4 months ago

My Bunny Portfolio Has Averaged a 13.7% Return

This article first appeared on GuruFocus. By John DorfmanDecember 8, 2025 (Maple Hill Syndicate) Today's column marks the 25th time I've written about a special collection of stocks I call the Bunny Portfolio, named after the Energizer B... Full story

Yahoo Finance • 5 months ago

The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a fur... Full story

Yahoo Finance • 5 months ago

Here are the major earnings after the close Thursday

Major earnings expected after the bell on Thursday include: * Block (XYZ [https://seekingalpha.com/symbol/XYZ]) * The Trade Desk (TTD [https://seekingalpha.com/symbol/TTD]) * Airbnb (ABNB [https://seekingalpha.com/symbol/ABNB]) *... Full story

Yahoo Finance • 6 months ago

Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling... Full story

Yahoo Finance • 7 months ago

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Presents a Compelling Value Investment Case

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH [https://www.chartmill.com/stock/quote/AMPH/profile]) has been identified as a potential candidate for value investors through a screening process that emphasizes strong fundamental valuation whil... Full story

Yahoo Finance • 8 months ago

Bullish Two Hundred Day Moving Average Cross - AMPH

In trading on Friday, shares of Amphastar Pharmaceuticals Inc (Symbol: AMPH) crossed above their 200 day moving average of $47.00, changing hands as high as $48.04 per share. Amphastar Pharmaceuticals Inc shares are currently trading up a... Full story

Yahoo Finance • 8 months ago

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vi... Full story

Yahoo Finance • 8 months ago

Amphastar boosts pipeline with exclusive licensing deal from Nanjing Anji

Amphastar Pharmaceuticals (NASDAQ:AMPH [https://seekingalpha.com/symbol/AMPH]) has entered [https://seekingalpha.com/pr/20197044-amphastar-pharmaceuticals-bolsters-proprietary-pipeline-through-exclusive-licensing-agreement] into an exclusi... Full story

Yahoo Finance • 8 months ago

Amphastar stock rises after FDA approves generic iron sucrose injection

Investing.com -- Amphastar Pharmaceuticals (NASDAQ:AMPH) stock gained 4% after the company announced FDA approval for its generic version of iron sucrose injection, a treatment for iron deficiency anemia in patients with chronic kidney dis... Full story

Yahoo Finance • 8 months ago

Piper Sandler lowers Amphastar Pharmaceuticals stock price target on competitive headwinds

Investing.com - Piper Sandler lowered its price target on Amphastar Pharmaceuticals (NASDAQ:AMPH) to $25.00 from $30.00 on Friday, while maintaining a Neutral rating on the stock. The stock, currently trading at $21.62, is near its 52-week... Full story

Yahoo Finance • 8 months ago

Amphastar advances U.S. manufacturing expansion and signals flat 2025 revenue outlook amid competitive pressures

Earnings Call Insights: Amphastar Pharmaceuticals (AMPH) Q2 2025 MANAGEMENT VIEW * Dan Dischner, Senior Vice President of Corporate Communications, highlighted that Amphastar delivered a solid performance in Q2 2025, underpinned by "th... Full story

Yahoo Finance • 9 months ago

Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White... Full story

Yahoo Finance • 9 months ago

JPMorgan Downgrades Amphastar Pharmaceuticals (AMPH) to Neutral from Overweight, Brings PT Down to $30

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On May 12, JPMorgan downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to Neutral from Overweight, while also reducing... Full story

Yahoo Finance • 9 months ago

Amphastar Pharmaceuticals stock hits 52-week low at 22.6 USD

Amphastar Pharmaceuticals (NASDAQ:AMPH) stock reached a 52-week low, trading at 22.6 USD. According to InvestingPro analysis, the company appears undervalued despite maintaining strong fundamentals with a P/E ratio of 7.88 and healthy liqu... Full story